Ardelyx Awaiting Next Steps From FDA To Resubmit NDA For Tenapanor For Hyperphosphatemia

Biopharmaceutical company Ardelyx, Inc. (ARDX) announced Wednesday that the company has met with the U.S. Food and Drug Administration (FDA) in a Type A meeting, but was not provided sufficient clarity on what constitutes "clinical relevance of the magnitude of treatment effect" and continues to await additional information regarding the path forward for the company's New Drug Application (NDA) for tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

The company said it continues to be extremely disappointed and surprised by the lack of clarity from the FDA on the next steps to resubmit the NDA even after they have conducted the requisite registration studies, which met all primary and key secondary endpoints with no safety or other identified issues.

The company has made the extremely difficult decision to implement a restructuring plan that includes a significant reduction in operating costs and 65% of workforce to preserve cash resources and extend cash runway. It retained only the key employees needed to continue to support the regulatory process and work to achieve the goal to gain approval for tenapanor for hyperphosphatemia.

The restructuring plan is expected to be completed in December 2021. The company estimates that it will incur aggregate restructuring charges of approximately $2.3 million, which will be recorded primarily in the fourth quarter 2021, related to severance payments and other employee-related costs.

In July 2021, Ardelyx announced that it had received a complete response letter (CRL) from the FDA regarding the company's NDA for tenapanor for the control of serum phosphorus in adult patients with CKD on dialysis.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cryptocurrency Dogecoin's price jumped over 15% on Friday, but later lost some of the gains, after Tesla Inc. (TSLA) CEO Elon Musk announced that the luxury car maker will start accepting the meme cryptocurrency as payment for its merchandise. "Tesla merch buyable with Dogecoin," Musk tweeted on Friday. Dogecoin... US investment bank JPMorgan Chase & Co. reported Friday a profit for the fourth quarter that declined 14 percent from last year, hurt primarily by higher noninterest expense and lower credit reserve releases. Both adjusted earnings per share and revenues for the quarter topped analysts' expectations. Microsoft Corp. said its Board of Directors has initiated a review of the effectiveness of its workplace sexual harassment and gender discrimination policies and practices. The company has hired the law firm of Arent Fox to conduct the review mainly on sexual harassment investigations, including that of co-founder Bill Gates.
Follow RTT